Scientific letter
Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
Uso generalizado de Nirmatrelvir más ritonavir (Paxlovid): Algunos planteamientos
Read
165
Timeswas read the article
38
Total PDF
127
Total HTML
Share statistics
array:23 [ "pii" => "S2529993X23000412" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2022.04.014" "estado" => "S300" "fechaPublicacion" => "2023-02-01" "aid" => "2585" "copyright" => "Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Enferm Infecc Microbiol Clin. 2023;41:127-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S2529993X22002301" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2022.10.010" "estado" => "S300" "fechaPublicacion" => "2023-02-01" "aid" => "2580" "documento" => "article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Enferm Infecc Microbiol Clin. 2023;41:128-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Double N501Y mutation hindering its detection by RT-PCR kit widely used at Clinical Microbiology laboratories" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "128" "paginaFinal" => "129" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Doble mutación en N501Y que impide su identificación mediante un kit de RT-PCR de uso habitual en los laboratorios de Microbiología Clínica" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Mikel Urrutikoetxea-Gutierrez, Domingo Fernández Vecilla, María Carmen Nieto Toboso, José Luis Diaz de Tuesta Del Arco" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Mikel" "apellidos" => "Urrutikoetxea-Gutierrez" ] 1 => array:2 [ "nombre" => "Domingo" "apellidos" => "Fernández Vecilla" ] 2 => array:2 [ "nombre" => "María Carmen" "apellidos" => "Nieto Toboso" ] 3 => array:2 [ "nombre" => "José Luis" "apellidos" => "Diaz de Tuesta Del Arco" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213005X22001045" "doi" => "10.1016/j.eimc.2022.04.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X22001045?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X22002301?idApp=UINPBA00004N" "url" => "/2529993X/0000004100000002/v1_202302081247/S2529993X22002301/v1_202302081247/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2529993X22002155" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2022.10.007" "estado" => "S300" "fechaPublicacion" => "2023-02-01" "aid" => "2581" "copyright" => "Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Enferm Infecc Microbiol Clin. 2023;41:125-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Diagnosis at first sight</span>" "titulo" => "An unexpected cause of polyarthritis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "125" "paginaFinal" => "126" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Una causa inesperada de poliartritis" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1675 "Ancho" => 1675 "Tamanyo" => 499221 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Gram stain identifying gram-negative cocci-like bacteria that are grouped in pairs (diplococci), in “coffee-bean” shape (black arrows).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Manuel Gómez-Cerquera, Sandro Herrera-Darias, Araceli González-Cuevas" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Juan Manuel" "apellidos" => "Gómez-Cerquera" ] 1 => array:2 [ "nombre" => "Sandro" "apellidos" => "Herrera-Darias" ] 2 => array:2 [ "nombre" => "Araceli" "apellidos" => "González-Cuevas" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213005X22001069" "doi" => "10.1016/j.eimc.2022.04.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X22001069?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X22002155?idApp=UINPBA00004N" "url" => "/2529993X/0000004100000002/v1_202302081247/S2529993X22002155/v1_202302081247/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "127" "paginaFinal" => "128" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "David Sánchez Fabra, Tina Herrero Jordán" "autores" => array:2 [ 0 => array:4 [ "nombre" => "David" "apellidos" => "Sánchez Fabra" "email" => array:1 [ 0 => "davidsanchezfabra@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Tina" "apellidos" => "Herrero Jordán" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "F.E.A (Facultativo Especialistas de Área) de Medicina Interna, Servicio de Medicina Interna del Hospital Reina Sofía de Tudela, Tudela, Navarra, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "F.E.A (Facultativo Especialista de Área) de Neumología, Servicio de Medicina Interna del Hospital Reina Sofía de Tudela, Tudela, Navarra, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Uso generalizado de Nirmatrelvir más ritonavir (Paxlovid): Algunos planteamientos" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Nirmatrelvir plus Ritonavir (Paxlovid) will be used in Spain soon.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> Although the potential effect of the drug against COVID-19 infection has biochemical explanation and has been demonstrated in several in vitro studies,<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> final acceptance arrived from the Randomized Clinical Trial (RCT) supported by Pfizer and published by Hammond et al.,<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> which was carried out in patients who were neither vaccinated nor had previously had COVID-19 infection, with a mild COVID-19 infection of less than 5 days. Despite the spectacular results of this RCT, several concerns should be considered.</p><p id="par0010" class="elsevierStylePara elsevierViewall">First, patients with at least one risk factor for severe COVID-19 disease were selected. These risk factors were, among others, being over 60 years of age, having a Body Mass Index (BMI) greater than 25 or having one of several relatively prevalent diseases such as high blood pressure, smoking, heart disease or lung disease. It is necessary to highlight that the proportion of people with at least one risk factor in our environment is very high. More than 40% of the Spanish population would have a BMI<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>25<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a> or almost 20% of the population is over 65 years old,<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a> which could mean an excessive number of potentially treatable patients.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Another important point to keep in mind is that the composite variable “admission or death” was chosen as outcome. Thanks to this, the Number Needed to Treat (NNT) to avoid an outcome was 18 patients (event rate in the treatment group of 0.78% vs. 6.40% in the placebo group; absolute risk reduction of 5.62%). However, when analysing events, we found that death was 18.2% of events (12/66 cases). Looking only at deaths, risk reduction was 1.15% (0% vs 1.15%) with an NNT of 87 patients. Mortality could be more useful to take decisions since many admissions may be short and perfectly assumable nowadays. Thus, it is essential to deepen into the characteristics of patients with adverse outcomes, both in terms of their comorbidities as well as the implications of such admission (stay, clinical severity, maximum need for oxygen flow or admission to the ICU), the latter being missed from the study.</p><p id="par0020" class="elsevierStylePara elsevierViewall">It should also be noted at this point that it seems that COVID-19 disease is beginning to behave like any other viral infection with the potential effect of producing community-acquired pneumonia (CAP). An unintended fact that emerges from the article is that mortality in unvaccinated patients with risk factors in the placebo group was only 1.15%. We must not lose sight of the fact that CAP has an incidence and hospitalization rate of 4.63 and 1.64 cases per 1000 people/year in Spain,<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">6,7</span></a> with a mortality of 4–18% in hospitalized patients, increasing dramatically in those with one or several comorbidities,<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a> and that most of them are caused by viruses.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Regarding the results, it seems clear that Paxlovid has a beneficial effect in preventing worsening of COVID-19 disease in selected mild patients with less than 5 days of symptoms, which is a promising milestone in the development of antiviral agents. Despite this, prudence is needed when regulating and using this medicine. When extrapolating the data to our daily clinical practice, and despite the fact that Pfizer is already carrying out another similar RCT in vaccinated patients (EPIC-Standard Risk [SR]; <a href="ctgov:NCT05011513">NCT05011513</a>), it is important to be aware that at the moment there is only one published RCT and that it has been carried out in unvaccinated population that had not had COVID-19 disease. In Spain, at the end of March 2022, more than 80% of the population has been vaccinated and one in four people has already overcome the disease.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a> Thus, clinicians should perform optimal risk stratification before prescribing such drug so that Paxlovid does not become inappropriately used.</p><p id="par0030" class="elsevierStylePara elsevierViewall">It may seem obvious, but we must not forget that the process of approving new drugs requires prudence, and although at the worst of the pandemic it was necessary to practice a medicine that was not strictly based on the evidence, fact that we all remember well, our situation today is no longer critical. That is why it is more necessary than ever to recover the scepticism and critical sense usually associated with scientific methodology, as well as the individual common sense of the art and science of medical practice.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "host" => array:1 [ 0 => array:1 [ "WWW" => array:1 [ "link" => "https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=5694" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Nirmatrelvir más ritonavir (Paxlovid) una potente combinación inhibidora de la proteasa 3CLpro del SARS-CoV-2" "tituloTraducido" => "Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Reina" 1 => "C. Iglesias" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.37201/req/002.2022" "Revista" => array:2 [ "tituloSerie" => "Rev Esp Quimioter" "fecha" => "2022" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Hammond" 1 => "H. Leister-Tebbe" 2 => "A. Gardner" 3 => "P. Abreu" 4 => "W. Bao" 5 => "W. Wisemandle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2118542" "Revista" => array:2 [ "tituloSerie" => "N Engl J Med" "fecha" => "2022" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of obesity and diabetes in Spanish adults 1987–2012" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F.J. Basterra-Gortari" 1 => "M. Bes-Rastrollo" 2 => "M. Ruiz-Canela" 3 => "A. Gea" 4 => "M.Á. Martinez-Gonzalez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.medcli.2016.11.022" "Revista" => array:6 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2017" "volumen" => "148" "paginaInicial" => "250" "paginaFinal" => "256" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28081903" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "host" => array:1 [ 0 => array:1 [ "WWW" => array:1 [ "link" => "https://www.ine.es/jaxiT3/Datos.htm?t=1488" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Rivero-Calle" 1 => "J. Pardo-Seco" 2 => "P. Aldaz" 3 => "D.A. Vargas" 4 => "E. Mascarós" 5 => "E. Redondo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "BMC Infect Dis" "fecha" => "2016" "volumen" => "16" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trends in hospitalizations for community-acquired pneumonia in Spain: 2004–2013" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. De Miguel-Díez" 1 => "R. Jiménez-García" 2 => "V. Hernández-Barrera" 3 => "I. Jiménez-Trujillo" 4 => "J.M. De Miguel-Yanes" 5 => "M. Méndez-Bailón" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejim.2016.12.010" "Revista" => array:6 [ "tituloSerie" => "Eur J Intern Med" "fecha" => "2017" "volumen" => "40" "paginaInicial" => "64" "paginaFinal" => "71" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27979670" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pneumonia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Torres" 1 => "C. Cilloniz" 2 => "M.S. Niederman" 3 => "R. Menéndez" 4 => "J.D. Chalmers" 5 => "R.G. Wunderink" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41572-021-00259-0" "Revista" => array:5 [ "tituloSerie" => "Nat Rev Dis Primers" "fecha" => "2021" "volumen" => "7" "paginaInicial" => "25" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33833230" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Advances in the causes and management of community acquired pneumonia in adults" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R.G. Wunderink" 1 => "G. Waterer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/bmj.j2471" "Revista" => array:4 [ "tituloSerie" => "BMJ" "fecha" => "2017" "volumen" => "358" "paginaInicial" => "j2471" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:1 [ "host" => array:1 [ 0 => array:1 [ "WWW" => array:1 [ "link" => "https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/situacionActual.htm" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/2529993X/0000004100000002/v1_202302081247/S2529993X23000412/v1_202302081247/en/main.assets" "Apartado" => array:4 [ "identificador" => "63562" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Scientific letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/2529993X/0000004100000002/v1_202302081247/S2529993X23000412/v1_202302081247/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X23000412?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 1 | 0 | 1 |
| 2024 October | 7 | 5 | 12 |
| 2024 September | 13 | 1 | 14 |
| 2024 August | 16 | 2 | 18 |
| 2024 July | 10 | 6 | 16 |
| 2024 June | 5 | 4 | 9 |
| 2024 May | 7 | 1 | 8 |
| 2024 April | 6 | 2 | 8 |
| 2024 March | 12 | 2 | 14 |
| 2024 February | 2 | 0 | 2 |
| 2024 January | 14 | 1 | 15 |
| 2023 December | 5 | 6 | 11 |
| 2023 November | 7 | 0 | 7 |
| 2023 October | 9 | 4 | 13 |
| 2023 September | 7 | 0 | 7 |
| 2023 August | 4 | 0 | 4 |
| 2023 March | 1 | 4 | 5 |
| 2023 February | 1 | 0 | 1 |
Show all
